The National Authority for Assessment and Accreditation in Healthcare (INEAS), the Health Technology Assessment (HTA) body in Tunisia, conducted a de novo cost-effectiveness analysis of vemurafenib for the treatment of locally advanced or metastatic BRAF V600-mutated melanoma in Tunisia. Here, BRAF is linked to melanoma.